DEVICE AND METHOD OF MONITORING A PATIENT

• US 20130183681A1
• Filed: 03/07/2013
• Published: 07/18/2013
• Est. Priority Date: 03/29/2005
• Status: Abandoned Application

• Current Assignee: Alere Switzerland GmbH (Abbott Laboratories)
• Original Assignee: Alere Switzerland GmbH (Abbott Laboratories)
• Inventors: McAleer, Jerry
• Application Number:
  US13/789,366
• Publication Number:
  US 20130183681A1
• Time in Patent Office: Days
• US Class Current: 435/7.1
• CPC Class Codes: A61B 5/0205 Simultaneously evaluating both cardiovascular conditions and different types of body conditions, e.g. heart and respiratory condition
• CPC Class Codes: A61B 5/14546 for measuring analytes not otherwise provided for, e.g. ions, cytochromes
• CPC Class Codes: A61B 5/7275 Determining trends in physiological measurement data; Predicting development of a medical condition based on physiological measurements, e.g. determining a risk factor
• CPC Class Codes: G01N 2800/325 Heart failure or cardiac arrest, e.g. cardiomyopathy, congestive heart failure
• CPC Class Codes: G01N 2800/52 Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
• CPC Class Codes: G01N 33/53 Immunoassay; Biospecific binding assay; Materials therefor
• CPC Class Codes: G01N 33/6893 related to diseases not provided for elsewhere
• CPC Class Codes: G16H 10/40 for data related to laboratory analysis, e.g. patient specimen analysis
• CPC Class Codes: G16H 10/60 for patient-specific data, e.g. for electronic patient records
• CPC Class Codes: G16H 40/67 for remote operation
• CPC Class Codes: G16H 50/20 for computer-aided diagnosis, e.g. based on medical expert systems

Abstract

A device for remote management of patients suffering or likely to suffer from heart failure that can measure the amplitude and frequency changes of one or more biomarkers. The device aids in predicting the need for medical intervention in such patients. The device may further aid in monitoring the efficacy and safety of treatment in such patients.

Claims

1. A system for monitoring heart failure in a patient in a home setting, comprising:

a plurality of sampling devices, wherein each sampling device is configured to obtain a body fluid sample from the patient;

an assay instrument, wherein the assay instrument is configured to determine a series of concentrations of a marker of left ventricular volume overload or myocardial stretch, each concentration in the series determined by introducing a body fluid sample obtained from the patient using one of the sampling devices into the assay instrument which (i) contacts the sample with an antibody under conditions such that immunospecific binding of the marker in the sample to the antibody occurs, and (ii) determines the concentration from the amount of the marker bound by the antibody;

a computer storage medium which receives and stores each concentration in the series;

a computer processor operably connected to the computer storage medium and configured to process the series of concentrations recorded on the computer storage medium by comparing one or more of the concentrations in the series of concentrations to a threshold value determined from the series of concentrations, wherein an excursion indicative of heart failure decompensation is identified by a concentration which is greater than the threshold concentration; and

a display device operably connected to the processor and configured to alert the patient or the patient'"'"'s physician when an excursion indicative of heart failure decompensation is identified by displaying an alert.

2. A method of monitoring heart failure patient for potential decompensation, comprising:

measuring a series of concentrations of a marker of left ventricular volume overload or myocardial stretch on body fluid samples taken from a patient at a predetermined regular interval in the patient'"'"'s home, each concentration in the series determined by introducing a body fluid sample obtained from the patient into an assay instrument which (i) contacts the sample with an antibody under conditions such that immunospecific binding of the marker in the sample to the antibody occurs, and (ii) determines the concentration from the amount of the marker bound by the antibody;

recording each concentration in the series of concentrations on a computer storage medium;

processing the series of concentrations recorded on the computer storage medium using a processor operably connected to the computer storage medium by comparing one or more of the concentrations in the series of concentrations to a threshold value determined from the series of concentrations, wherein an excursion indicative of heart failure decompensation is identified by a concentration which is greater than the threshold concentration; and

alerting the patient or the patient'"'"'s physician when an excursion indicative of heart failure decompensation is identified by displaying an alert on a display device operably connected to the processor.

3. A method according to claim 2, wherein the body fluid sample is introduced into the assay instrument by introducing the body fluid sample into a single use test cartridge which comprises the antibody, and wherein the single use test cartridge is read by a test cartridge reader component of the assay instrument for determining the concentration from the amount of the marker bound by the antibody.

4. A method according to claim 2, wherein the marker is BNP or its N-terminal prohormone.

5. A method according to claim 2, wherein the display device is located at a remote location from the patient'"'"'s home.

6. A method according to claim 2, wherein the display device is located on the assay instrument.

7. A method according to claim 6, further comprising displaying an alert at a remote location from the patient'"'"'s home.

8. A method according to claim 2, wherein the predetermined interval is a daily measurement of the marker, and the concentration series is obtained over at least four days.

9. A method according to claim 2, wherein the body fluid sample is blood, serum, or plasma.